Examining the EVIDENCE

Does the discontinuation of menopausal hormone therapy affect a woman’s cardiovascular risk?

No. Although findings from this large observational study from Finland suggest that women stopping hormone therapy (HT) experienced elevations in cardiac and stroke mortality within the first year after discontinuation, these associations are not likely to be causal and contradict those of the Women’s Health Initiative, the largest randomized trial of HT, which found no elevated risks after discontinuation of HT.\(^1,2\)

This recently published study from Finland generated headlines when its authors concluded that stopping HT elevates the risk of mortality from cardiovascular disease (CVD), including cardiac and cerebrovascular events. Using nationwide data, investigators compared the CVD mortality rate among women who discontinued HT during the years 1994 through 2009 (n = 332,202) with expected (not actual) CVD mortality rates in the background population.

Within the first year after HT discontinuation, elevations in death rates from cardiac events and stroke were noted (standardized mortality ratio, 1.26 and 1.63, respectively), while in the subsequent year, reductions in such mortality were observed ($P<.05$ for all comparisons).

The absolute increased risk of death from cardiac events reported within the first year after discontinuation of HT was 4 deaths per 10,000 woman-years of exposure. The absolute risk of death from stroke was 5 additional events per 10,000 woman-years. This level of risk is considered to be rare.

CONTINUED ON PAGE 51
How these data compare to those of other studies

In contrast with these Finnish data, findings from the Women’s Health Initiative—the largest randomized trial of menopausal HT—do not indicate an increase in mortality or an increase in coronary heart or stroke events among women stopping HT.1,2

It seems likely that limitations associated with the Finnish observational data account for this discordance. For example, Mikkola and colleagues did not know why women discontinued HT, raising the possibility that women with symptoms suggestive of CVD or development of new risk factors preferentially stopped HT, potentially introducing important bias into the Finnish analysis.3

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Women and their clinicians should make decisions regarding whether to continue, reduce the dose, or discontinue HT through shared decision making, focusing on individual patient quality of life parameters as well as changing risk concerns related to such entities as cancer, CVD, and osteoporosis.3 Dramatic as they are, findings from this Finnish report should not impact how we counsel women regarding use or discontinuation of HT.

ANDREW M. KAUNITZ, MD; JOANN E. MANSON, MD, DRPH; AND CYNTHIA A. STUENKEL, MD

References


Do your patients have difficulty filling some of their HT prescriptions?

In his Editorial, “Does hormone therapy reduce mortality in recently menopausal women?” which appeared in the October 2015 issue of OBG MANAGEMENT, Editor in Chief Robert L. Barbieri, MD, expressed:

Many health insurers use pharmacy benefit managers to control the cost of prescription medicines. These managers often develop formulary algorithms that favor the use of oral estrogen and medroxyprogesterone acetate over transdermal estradiol and micronized progesterone.

He then posed this question to readers:

When you prescribe transdermal estradiol and micronized progesterone, have your patients had difficulty filling the prescription?

READERS WEIGH IN:

Yes!
The pharmacies push “cheaper” substitutions. I do a lot of education, but it is exhausting!

Julie Fryman, MD
Cumming, Georgia

Quick poll results

More than 130 readers weighed in, with:

• 69.9% (95 readers) indicating that their patients have had difficulty filling the prescriptions
• 30.1% (41 readers) indicating that their patients have not had difficulty filling the prescriptions

To participate in the latest Quick Poll, visit obgmanagement.com